<DOC>
	<DOC>NCT00806585</DOC>
	<brief_summary>The study will assess the efficacy and tolerability of MK0736 in patients with Type 2 Diabetes Mellitus and Hypertension who are on ongoing therapy with Angiotensin-Converting Enzyme or Angiotensin Receptor Blocker. After a 3 to 5 week pre-randomization phase, patients will be randomized to either MK0736 (3 doses), placebo, or hydrochlorothiazide (HCTZ). The study will also include a 3 week, posttreatment follow-up period.</brief_summary>
	<brief_title>Dose-ranging Study to Evaluate the Effectiveness and Tolerability of MK0736 in Patients With Type 2 Diabetes Mellitus (T2DM) and Hypertension (0736-007)</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<mesh_term>Angiotensin Receptor Antagonists</mesh_term>
	<criteria>Must be 18 to 75 years of age Type 2 Diabetes Mellitus (Glycohemoglobin [A1CHbA1c]: 7 to 10%) Hypertension: Diastolic blood pressure (DBP; 85 to 99 mm Hg) and systolic blood pressure (SBP; 120 to 159 mm Hg) LDLC &lt; 140 mg/dL On stable treatment with an AngiotensinConverting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) History of Type I Diabetes mellitus or ketoacidosis Patients taking 3 or more blood pressure lowering medications Have severe chronic heart failure History of certain diseases or conditions such as cardiac arrhythmias, heart attack, stroke, unstable angina, or decompensated vascular disease History of cancer within the last 5 years Human immunodeficiency virus (HIV) Positive Have received treatment with any investigational drugs within the past 30 days History of alcohol or drug abuse within the past 3 years Body Mass Index ( BMI) &gt;= 41 kg/m2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>